This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idera Pharmaceuticals Reports Preclinical Mechanism Of Action Data On IMO-8400, A Novel TLR Inhibitor For Autoimmune Diseases

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced results from preclinical studies evaluating the mechanism of action of IMO-8400, a selective inhibitor of Toll-like Receptors (TLRs) 7, 8, and 9. The data were presented on Wednesday, June 20, during the Federation of Clinical Immunology Societies (FoCIS) meeting being held June 20-23, 2012, in Vancouver, BC, Canada.

In this study, the mechanism of action of IMO-8400 has been studied in non-human primates. The administration of IMO-8400 led to inhibition of immune responses mediated through targeted Toll-like receptors. Multiple cytokines were suppressed, including TNF-α, IL-12, IL-6, IFN-α, IL-1β. Similar results of IMO-8400 suppression of TLR7, 8 and 9-mediated immune responses were observed in human blood cells. IMO-8400 is a lead candidate in development for the treatment of lupus.

"These studies confirm that in a preclinical primate model and in human blood cells treatment with IMO-8400 specifically blocked cytokine induction mediated through targeted TLRs," said Tim Sullivan, VP of Development Programs and Alliance Management. "The selective inhibition of these TLRs is consistent with the preclinical efficacy we have seen in commonly used mouse models of lupus and holds promise for potential use of IMO-8400 in humans with lupus and other autoimmune diseases. The activity demonstrated with IMO-8400 in various models forms the basis for the Investigational New Drug Application we anticipate submitting to the FDA in the fourth quarter of this year."

About TLRs and Idera's Pipeline

Toll-like Receptors (TLRs) represent a class of proteins that play a key role in both inflammation and immunity. Of the 10 human TLRs identified to date, Idera is focusing on compounds targeted to TLRs 3, 7, 8, and 9, which are expressed in different cells and serve unique functions. For example, activation of TLR7 and TLR9 present in certain dendritic cells and lymphocytes may be useful for the treatment of various types of cancer by stimulating immunity. In contrast, inhibition of specific TLRs may be useful in treating autoimmune disorders, such as psoriasis and lupus, by blocking the production of multiple pro-inflammatory mediators. Using its chemistry-based approach, Idera has developed novel drug candidates which modulate immune response through activation or inhibition of specific TLRs to treat a broad range of diseases, including autoimmune diseases and cancer, and to enhance the effectiveness of vaccines.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.42 -1.50%
FB $116.23 -0.43%
GOOG $691.59 0.08%
TSLA $241.07 -2.70%
YHOO $36.31 -0.77%


Chart of I:DJI
DOW 17,677.25 -153.51 -0.86%
S&P 500 2,057.17 -18.64 -0.90%
NASDAQ 4,755.0480 -50.2430 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs